Ketorolac Trometamol S.A.L.F. (Ketorolac Trometamol)

The drug works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This inhibition blocks the conversion of arachidonic acid to prostaglandins, reducing the inflammatory mediators that cause pain, swelling, and fever, thereby providing effective analgesia.

The exact dose of Ketorolac Trometamol is determined by the prescribing clinician based on the patient’s condition, age, renal function, and route of administration. Typical dosing regimens range from a single dose to a short course, but the prescriber sets the precise amount and schedule.

Data on the use of Ketorolac Trometamol during pregnancy and lactation are limited, and the drug is generally avoided, especially in the third trimester, because of potential risks to the fetus and newborn. Healthcare providers should weigh benefits against possible hazards before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ketorolac Trometamol is considered one of the more potent NSAIDs for short‑term pain control and is available only for injectable use, allowing rapid onset. Compared with oral NSAIDs, it provides stronger analgesia but carries a higher risk of gastrointestinal and renal adverse effects, so its use is limited to brief periods.

The product should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and ensure they are not frozen. Follow standard aseptic handling procedures when preparing for intramuscular or intravenous administration.

Ketorolac Trometamol is supplied as an injectable solution and may be given either intramuscularly or intravenously. The route, injection site, and rate of administration are determined by the prescribing clinician, who will also monitor the patient for any immediate adverse reactions during and after the injection.

Serious risks include gastrointestinal bleeding or ulceration, severe allergic reactions such as anaphylaxis, and renal impairment, especially in patients with pre‑existing kidney disease. Cardiovascular events such as myocardial infarction or stroke can also occur, particularly with prolonged use or in high‑risk individuals.

Ketorolac Trometamol should be avoided in patients with known hypersensitivity to ketorolac or other NSAIDs, active peptic ulcer disease, significant renal impairment, uncontrolled hypertension, and those receiving anticoagulant therapy where bleeding risk is high. It is also contraindicated in the third trimester of pregnancy.